H.R. 3676 is a one-purpose bill: it declares that Executive Order 14293 (90 Fed. Reg. 19615), described as directing regulatory relief to promote domestic production of critical medicines, "shall have the force and effect of law." The bill does not reproduce the text of the executive order, amend existing statutes, allocate funds, or include implementing language.
That simple change — converting an executive order into statutory law by reference — is legally significant. It elevates presidential policy choices into binding law, shifts the locus of implementation to federal agencies, and creates uncertainty about scope, enforcement, appropriations, and judicial review.
Compliance officers, agency counsel, and manufacturers will need to assess what actions agencies can take under existing statute once the order is codified.
At a Glance
What It Does
The bill adopts Executive Order 14293 by reference and declares that the order "shall have the force and effect of law." It does not reproduce the EO's text, add implementing regulations, or provide funding or an effective date separate from enactment.
Who It Affects
Federal agencies that regulate drug development and manufacturing (for example, HHS and FDA) will carry primary implementation responsibility; domestic pharmaceutical manufacturers, contract manufacturers, and supply-chain logistics firms will feel the operational impact. States and investors focused on onshoring medicines are also implicated.
Why It Matters
Turning an executive order into statute changes the legal footing for agency action, potentially narrowing judicial challenges based on executive authority but exposing implementation to statutory constraints, appropriations issues, and the Administrative Procedure Act. Professionals should evaluate compliance, enforcement, and litigation risk rather than assume the EO's operational details automatically become enforceable.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill does one narrow thing: it makes Executive Order 14293 into federal law by saying the order "shall have the force and effect of law." That means the policy directions contained in the executive order — whatever they are in the Federal Register notice — are no longer only presidential instructions but have statutory status if the bill becomes law.
Because the bill incorporates the EO by reference instead of printing its language, anyone implementing or challenging the new statute will need to consult the Federal Register citation the bill identifies. The bill contains no text that changes existing statutes (for example, the Food, Drug, and Cosmetic Act) and it does not supply funding or authorize particular agency rulemaking steps.
Agencies will therefore implement the codified EO within the constraints of their current statutory authorities and budgetary limits.The change in legal status alters the litigation landscape. Some legal challenges that rely on arguments about executive overreach may be muted if the policy is now statutory; conversely, parties can challenge agency actions under the Administrative Procedure Act or assert that agencies lack statutory authority to carry out specific provisions of the EO.
Courts may confront threshold questions about whether adopting an EO by reference into a statute satisfies requirements for statutory clarity and legislative drafting.For regulated entities, the practical effect will depend on what agencies do next. If agencies promulgate relaxed regulations, guidance, or expedited pathways invoking the codified EO, manufacturers may see lower regulatory barriers or faster approvals — but only where agencies have clear statutory authority and resources.
Absent appropriations or explicit statutory amendments, the codification primarily changes the legal frame rather than guaranteeing operational change on the ground.
The Five Things You Need to Know
The bill declares that Executive Order 14293 (90 Fed. Reg. 19615) "shall have the force and effect of law," thereby elevating the order's content to statutory status by reference.
H.R. 3676 does not reproduce the text of the executive order in the bill; it points implementers and litigants to the Federal Register citation rather than enacting language.
The bill contains no implementing instructions, amendments to existing statutes, appropriations, or express effective date or sunset.
Implementation responsibility falls to federal agencies — which must act within their existing statutory authorities and budget limits to give effect to the codified order.
The method of codification raises predictable legal questions (statutory clarity, APA review, and major-questions/nondelegation doctrines) that are likely to determine how broadly courts allow agencies to act under the new statute.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act's short name, the "Executive Order 14293 Act of 2025." This is a housekeeping provision used for citation; it does not affect substance or implementation. Practically, it tells readers and drafters how to refer to the law in legal and administrative contexts.
Codification of Executive Order 14293
This is the operative text: it states that Executive Order 14293 (as published at 90 Fed. Reg. 19615) "shall have the force and effect of law." The provision enacts the EO's policy by reference rather than by reproducing statutory language. That drafting choice shifts questions about meaning and scope to the EO's published text and to subsequent agency actions, while leaving intact any statutory constraints that already limit agency authority and leaving funding decisions to regular appropriations processes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Domestic pharmaceutical manufacturers and contract drug producers — They stand to gain if agencies use the codified authority to reduce regulatory friction, expedite approvals, or prioritize domestic production, improving business prospects for onshore facilities.
- State economic development agencies and localities hosting manufacturing plants — Codification signals federal prioritization of domestic production, which can bolster investment, grants, and public-private partnerships aimed at expanding local manufacturing capacity.
- Policymakers and advocates focused on supply-chain resilience — They receive a statutory tool that can be cited in oversight, procurement, and industry engagement to push for domestic sourcing of critical medicines.
Who Bears the Cost
- Federal regulatory agencies (notably HHS and FDA) — Agencies will bear the administrative and legal burden of executing the codified EO without additional appropriations, including potential rulemaking, guidance drafting, and increased litigation exposure.
- Taxpayers and appropriators — If agencies require new programs or incentives to implement the EO's policy goals, Congress will face pressure to provide funding; absent that, agencies may need to reprioritize existing resources.
- Foreign suppliers and multinational manufacturers — Firms that currently supply critical medicines from abroad could lose market share if domestic production is incentivized or regulatory relief tilts the playing field toward U.S. facilities.
- Manufacturers lacking scale or compliance capacity — Those unable to expand quickly may face competitive pressure or comply with new expedited but potentially costly requirements.
Key Issues
The Core Tension
The central dilemma is speed versus statutory process: codifying the executive order moves quickly to make a presidential policy binding, which can accelerate actions to shore up domestic medicine production, but doing so risks bypassing the deliberative, budgetary, and statutory safeguards that limit executive and administrative power — a trade-off that creates implementation uncertainty and invites judicial scrutiny.
Codifying an executive order by reference is legally efficient but raises technical and constitutional issues. Because the bill does not reproduce the EO's text, courts and implementers must rely on the Federal Register notice to determine statutory content.
That raises questions about whether a statute created by reference provides the necessary precision courts expect in a law, particularly if agencies interpret the EO expansively. Separately, codification does not create additional agency powers beyond existing statutes; agencies that try to use the codified EO to take actions that exceed their authorizing statutes will face challenges under the Administrative Procedure Act and possibly the major-questions or nondelegation doctrines.
Operationally, the bill leaves funding and implementation details unresolved. It contains no appropriations, no implementation timetable, and no directive for specific rulemaking procedures.
Agencies could issue guidance or use existing authorities to implement the EO's aims, but meaningful changes (grants, subsidies, procurement commitments, or statutory exemptions) typically require congressional funding or explicit statutory amendments. That mismatch between policy ambition and legislative mechanics may produce uneven results across agencies and invite litigation that tests how far a codified EO can reach without separate statutory authorization.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.